Amsacrine

Amsacrine

File:Amsacrine.svg
Clinical data
ATC code	L01XX01 (WHO)
Pharmacokinetic data
Protein binding	96 to 98%
Elimination half-life	8-9 hours
Identifiers
IUPAC name N-(4-(acridin-9-ylamino)-3-methoxyphenyl)methanesulfonamide
CAS Number	51264-14-3
PubChem CID	2179
DrugBank	APRD00064
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C21H19N3O3S
Molar mass	393.46 g/mol

WikiDoc Resources for Amsacrine
Articles
Most recent articles on Amsacrine Most cited articles on Amsacrine Review articles on Amsacrine Articles on Amsacrine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Amsacrine Images of Amsacrine Photos of Amsacrine Podcasts & MP3s on Amsacrine Videos on Amsacrine
Evidence Based Medicine
Cochrane Collaboration on Amsacrine Bandolier on Amsacrine TRIP on Amsacrine
Clinical Trials
Ongoing Trials on Amsacrine at Clinical Trials.gov Trial results on Amsacrine Clinical Trials on Amsacrine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Amsacrine NICE Guidance on Amsacrine NHS PRODIGY Guidance FDA on Amsacrine CDC on Amsacrine
Books
Books on Amsacrine
News
Amsacrine in the news Be alerted to news on Amsacrine News trends on Amsacrine
Commentary
Blogs on Amsacrine
Definitions
Definitions of Amsacrine
Patient Resources / Community
Patient resources on Amsacrine Discussion groups on Amsacrine Patient Handouts on Amsacrine Directions to Hospitals Treating Amsacrine Risk calculators and risk factors for Amsacrine
Healthcare Provider Resources
Symptoms of Amsacrine Causes & Risk Factors for Amsacrine Diagnostic studies for Amsacrine Treatment of Amsacrine
Continuing Medical Education (CME)
CME Programs on Amsacrine
International
Amsacrine en Espanol Amsacrine en Francais
Business
Amsacrine in the Marketplace Patents on Amsacrine
Experimental / Informatics
List of terms related to Amsacrine

Overview

Amsacrine is an antineoplastic agent. Its planar fused ring system can intercalate into the DNA of tumor cells, thereby altering the major and minor groove proportions. These alterations to DNA structure inhibit both DNA replication and transcription by reducing association between the affected DNA and: DNA polymerase, RNA polymerase and transcription factors.

Amsacrine also expresses topoisomerase inhibitor activity, specifically inhibiting topoisomerase II (compares with the better known agent etoposide).